BACIL PHARMA LIMITED

CIN: L24200MH1987PLC043427
Registered Office: G2 & G3, Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai - 400099;
Tel: 22618452/22661541; Tel/Fax: 22618327; Email Id: bacilpha@yahoo.com/ bacilpharma07@gmail.com**; Website:** www.bacilpharma.com

Date: 25/11/2026

To,
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.

Scrip Code: 524516

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Execution of Memorandum of Understanding for proposed acquisition of immovable property for establishment of Research & Development Centre.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Board of Directors of the **Bacil Pharma Limited ("the Company") has entered into a Memorandum of Understanding (MOU) with Shri Gaurang M. Shah and Smt. Chhaya G. Shah for the proposed purchase of an immovable property situated at Flat No. G2-G3, Ground Floor, Samarpan Complex, Link Road, Opposite Solitaire Park, Next to Mirador Hotel, Andheri East, Mumbai – 400099, admeasuring approximately 3,300 sq. ft.**

The total agreed consideration for the proposed acquisition of the said property is **₹12.50 Crore (Rupees Twelve Crore Fifty Lakh Only)**, subject to the terms and conditions stipulated in the MOU and execution of the definitive sale and transfer documents.

The Company has paid an advance/token amount of ₹ 10,00,000/- towards the proposed purchase consideration, and the balance consideration shall be paid in accordance with the terms agreed between the parties.

Purpose of Acquisition:

The proposed property is intended to be utilised by the Company for establishing and developing a dedicated **Research & Development (R&D) Centre**. The proposed facility is expected to strengthen the Company's research capabilities, support product development, enhance technical infrastructure and create opportunities for future business growth.

Proposed Funding:

The Company proposes to raise funds through a **Rights Issue of equity shares**, subject to necessary approvals and applicable statutory and regulatory requirements. The proceeds of the proposed Rights Issue are intended to be utilised towards funding the acquisition of the aforesaid property, in accordance with the objects and terms of the Rights Issue.

The proposed acquisition represents a strategic step towards strengthening the Company's infrastructure and establishing its own R&D facility for long-term business development.

The transaction shall be completed subject to fulfilment of the terms and conditions of the MOU, completion of necessary legal and property due diligence, execution of definitive documents and applicable statutory approvals, wherever required.

BACIL PHARMA LIMITED

CIN: L24200MH1987PLC043427
Registered Office: G2 & G3, Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai - 400099;
Tel: 22618452/22661541; Tel/Fax: 22618327; Email Id: bacilpha@yahoo.com/ bacilpharma07@gmail.com**; Website:** www.bacilpharma.com

The requisite details of the transaction are provided in the Annexure enclosed herewith.

Authorisation for Execution of MOU:

The Board of Directors of the Company has authorised Mrs, Chaitali Kalpataru Shah, Director of the Company, to undertake all necessary acts, deeds and things, complete the requisite formalities, negotiate and finalise the terms and conditions, and execute and sign the Memorandum of Understanding (MOU) and other necessary documents on behalf of the Company in connection with the proposed acquisition of the aforesaid property. Accordingly, Mrs. Chaitali Kalpataru Shah has been authorised to represent the Company and take all necessary steps to give effect to the proposed transaction.

This is for your information and records.

Thanking you,

For Bacil Pharma Limited

Shah Chaitali Kalpataru
Digitally signed by Shah Chaitali Kalpataru
Date: 2026.11.25 14:14:34 +05'30'

Chaitali Kalpataru Shah
Director & CFO
DIN: 11167778

BACIL PHARMA LIMITED

CIN: L24200MH1987PLC043427

Registered Office: G2 & G3, Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai - 400099;
Tel: 22618452/22661541; Tel/Fax: 22618327; Email Id: bacilpha@yahoo.com/ bacilpharma07@gmail.com**; Website:** www.bacilpharma.com

Annexure – Details of the proposed transaction

The disclosure should include the prescribed material particulars, as applicable, under Regulation 30 and the SEBI Master Circular dated January 30, 2026.

Particulars	Details
Name of seller	Shri Gaurang M. Shah and Smt. Chhaya G. Shah
Nature of transaction	Proposed purchase of immovable property
Property	Flat No. G2-G-3, Ground Floor, Samarpan Complex
Location	Andheri East, Mumbai – 400099
Area	Approximately 3,300 sq. ft.
Total consideration	₹12.50 crore
Advance paid	₹10,00,000/-
Balance consideration	₹12.40 crore
Mode of funding	Proposed Rights Issue
Purpose	Establishment of Research & Development Centre
Related party transaction	To be confirmed
Promoter/Promoter Group interest	To be confirmed
Regulatory approvals	As applicable
Expected completion	Within the period agreed under the MOU, subject to its terms